SCHEMBL3901552

SCHEMBL3901552

CCCCCC(CN(O)C=O)C(=O)NS(C)(=O)=O

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BMP1 P13497 7/20 0.49
MMP12 P39900 1/20 0.44
PDF Q9HBH1 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3903238 0.86 BMP1 (0.45) BMP1MMP12
SCHEMBL3900855 0.86 BMP1 (0.45) BMP1MMP12PDF
SCHEMBL20824837 0.82 CA2 (0.44)
SCHEMBL1597846 0.81 CA1 (0.54) BMP1MMP12PDF
SCHEMBL1597847 0.81 CA1 (0.54) BMP1MMP12PDF
SCHEMBL1597844 0.81 CA1 (0.54) BMP1MMP12PDF
SCHEMBL3900004 0.80 BMP1 (0.55) BMP1MMP12
SCHEMBL18954255 0.80 CA2 (0.47)
SCHEMBL5476347 0.80 BMP1 (0.48) BMP1MMP12PDF
SCHEMBL3895773 0.80 ALDH1A1 (0.47) BMP1MMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615629-B1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-03-18 EP claimed
US-7375120-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-05-20 US claimed
EP-1615629-A4 PEPTIDE DEFORMYLASE INHIBITORS CHRISTENSEN SIEGFRIED B IV (US) 2007-02-28 EP claimed
US-20060229341-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2006-10-12 US claimed
EP-1615629-A1 PEPTIDE DEFORMYLASE INHIBITORS Christensen, Siegfried B. IV (US) 2006-01-18 EP claimed
WO-2004098584-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-18 WO claimed
EP-1615629-B1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2009-03-18 EP disclosed
US-7375120-B2 Peptide deformylase inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2008-05-20 US disclosed
EP-1615629-A4 PEPTIDE DEFORMYLASE INHIBITORS CHRISTENSEN SIEGFRIED B IV (US) 2007-02-28 EP disclosed
US-20060229341-A1 Peptide deformylase inhibitors GLAXOSMITHKLINE LLC 2006-10-12 US disclosed
EP-1615629-A1 PEPTIDE DEFORMYLASE INHIBITORS Christensen, Siegfried B. IV (US) 2006-01-18 EP disclosed
WO-2004098584-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229341-A1 Peptide deformylase inhibitors PDF, PEPD, DPEP1 BMP1 1590/4885MMP12 1436/4885PDF 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.